Saltar al contenido
Merck

PD-1/PD-L1 blockade abrogates a dysfunctional innate-adaptive immune axis in critical β-coronavirus disease.

Science advances (2022-09-22)
Maite Duhalde Vega, Daniela Olivera, Gustavo Gastão Davanzo, Mauricio Bertullo, Verónica Noya, Gabriela Fabiano de Souza, Stéfanie Primon Muraro, Icaro Castro, Ana Paula Arévalo, Martina Crispo, Germán Galliussi, Sofía Russo, David Charbonnier, Florencia Rammauro, Mathías Jeldres, Catalina Alamón, Valentina Varela, Carlos Batthyany, Mariela Bollati-Fogolín, Pablo Oppezzo, Otto Pritsch, José Luiz Proença-Módena, Helder I Nakaya, Emiliano Trias, Luis Barbeito, Ignacio Anegon, María Cristina Cuturi, Pedro Moraes-Vieira, Mercedes Segovia, Marcelo Hill
RESUMEN

Severe COVID-19 is associated with hyperinflammation and weak T cell responses against SARS-CoV-2. However, the links between those processes remain partially characterized. Moreover, whether and how therapeutically manipulating T cells may benefit patients are unknown. Our genetic and pharmacological evidence demonstrates that the ion channel TMEM176B inhibited inflammasome activation triggered by SARS-CoV-2 and SARS-CoV-2-related murine β-coronavirus. Tmem176b-/- mice infected with murine β-coronavirus developed inflammasome-dependent T cell dysfunction and critical disease, which was controlled by modulating dysfunctional T cells with PD-1 blockers. In critical COVID-19, inflammasome activation correlated with dysfunctional T cells and low monocytic TMEM176B expression, whereas PD-L1 blockade rescued T cell functionality. Here, we mechanistically link T cell dysfunction and inflammation, supporting a cancer immunotherapy to reinforce T cell immunity in critical β-coronavirus disease.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-Rabbit IgG (H+L)-Biotin antibody produced in donkey, affinity isolated antibody, lyophilized powder